It is postulated that therapies targeted at their specific gene alterations may provide benefit, as NRAS and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations are common even in benign CMN before any progression to MM. This evidence concerns the gene NRAS and Miyoshi myopathy.